P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the
secondary prevention of thrombotic events in vascular diseases. Within the past few years …

Over the past decade there has been a revolution in the field of G protein-coupled receptor
(GPCR) structural biology. Many years of innovative research from different areas have …

Polypharmacy in patients undergoing coronary artery stenting or in those presenting with an
acute coronary syndrome is common. Nevertheless, the risk of drug–drug interactions in …

Introduction: The study of pharmacogenomics presents the possibility of individualised
optimisation of drug therapy tailored to each patients' unique physiological traits. Both …

Currently approved platelet adenosine diphosphate (ADP) receptor antagonists target only
the platelet P2Y 12 receptor. Moreover, especially in patients with acute coronary …

The aim of this study was to evaluate the distribution of platelet reactivity values in patients
treated with prasugrel and ticagrelor. This prospective observational study enrolled 200 …

Dual antiplatelet therapy with aspirin and clopidogrel in patients undergoing percutaneous
coronary intervention (PCI) and in patients with acute coronary syndromes (ACS) has …

Background and aims New antithrombotic therapies have significantly improved the
outcomes of patients with acute coronary syndrome (ACS), where the introduction of …

Ticagrelor (TCG), an antiplatelet agent, has low solubility and permeability; thus, there are
many trials to apply the pharmaceutical technology for the enhancement of TCG solubility …

Dual antiplatelet therapy (DAPT) is standard in acute coronary heart disease but confers a
bleeding risk. To compare the effects of ticagrelor‐monotherapy with ticagrelor‐based DAPT …